Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus NAPRELAN.
CHILDREN'S IBUPROFEN vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category D/X
Category C
NSAID
NSAID